ArticleJournal of managed care & specialty pharmacy2021

Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.

Eleanor Paul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.